Abafungin

Abafungin
Clinical data
Trade names	Abasol
Routes of; administration	Topical (cream)
ATC code	none;
Identifiers
	IUPAC name N-[4-[2-(2,4-dimethylphenoxy)phenyl]-1,3-thiazol-2-yl]-1,4,5,6-tetrahydropyrimidin-2-amine;
CAS Number	129639-79-8 ;
PubChem CID	159326;
ChemSpider	140124 ;
UNII	11DI31LWXF;
ChEBI	CHEBI:76005 ;
ECHA InfoCard	100.125.129
Chemical and physical data
Formula	C21H22N4OS
Molar mass	378.49 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=CC(=C(C=C1)OC2=CC=CC=C2C3=CSC(=N3)NC4=NCCCN4)C;
	InChI InChI=1S/C21H22N4OS/c1-14-8-9-18(15(2)12-14)26-19-7-4-3-6-16(19)17-13-27-21(24-17)25-20-22-10-5-11-23-20/h3-4,6-9,12-13H,5,10-11H2,1-2H3,(H2,22,23,24,25) ; Key:TYBHXIFFPVFXQW-UHFFFAOYSA-N ;
	(what is this?) (verify)

Abafungin (INN) is a broad-spectrum antifungal agent with a novel mechanism of action for the treatment of dermatomycoses.

Abasol is a topical cream formulation of abafungin by York Pharma.[1]

History

Abafungin was first synthesized at Bayer AG, Leverkusen, Germany. A study of H₂-antagonists related to famotidine, resulted in the discovery of its antifungal properties.[2]

Mechanism of action

Unlike imidazole- and triazole-class antifungals, abafungin directly impairs the fungal cell membrane.[2]

In addition, abafungin inhibits the enzyme sterol 24-C-methyltransferase, modifying the composition of the fungal membrane.[3]

Abafungin has antibiotic activity against gram-positive bacteria as well as sporicidal activity.[4]

References

"Regulatory Update – Abasol" (PDF). York Pharma. Archived from the original (PDF) on September 27, 2007.
Borelli C, Schaller M, Niewerth M, Nocker K, Baasner B, Berg D, et al. (August 2008). "Modes of action of the new arylguanidine abafungin beyond interference with ergosterol biosynthesis and in vitro activity against medically important fungi". Chemotherapy. 54 (4): 245–59. doi:10.1159/000142334. PMC 2818358. PMID 18587237. Retrieved 10 December 2018.
Ruiz-Ortega M, González S, Serón D, Condom E, Bustos C, Largo R, González E, Ortiz A, Egido J (December 1995). "ACE inhibition reduces proteinuria, glomerular lesions and extracellular matrix production in a normotensive rat model of immune complex nephritis". Kidney International. 48 (6): 1778–91. doi:10.1038/ki.1995.476. PMID 8587237.
Ginter-Hanselmayer G (March 2009). Arbeitsunterlagen zur 42. wissenschaftlichen Fortbildungsveranstaltung für Apothekerinnen und Apotheker: Infektionskrankheiten. Österreichische Apothekerkammer. p. 103.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] "Regulatory Update – Abasol" (PDF). York Pharma. Archived from the original (PDF) on September 27, 2007.

[BorelliEtAl2008-2] Borelli C, Schaller M, Niewerth M, Nocker K, Baasner B, Berg D, et al. (August 2008). "Modes of action of the new arylguanidine abafungin beyond interference with ergosterol biosynthesis and in vitro activity against medically important fungi". Chemotherapy. 54 (4): 245–59. doi:10.1159/000142334. PMC 2818358. PMID 18587237. Retrieved 10 December 2018.

[pmid8587237-3] Ruiz-Ortega M, González S, Serón D, Condom E, Bustos C, Largo R, González E, Ortiz A, Egido J (December 1995). "ACE inhibition reduces proteinuria, glomerular lesions and extracellular matrix production in a normotensive rat model of immune complex nephritis". Kidney International. 48 (6): 1778–91. doi:10.1038/ki.1995.476. PMID 8587237.

[4] Ginter-Hanselmayer G (March 2009). Arbeitsunterlagen zur 42. wissenschaftlichen Fortbildungsveranstaltung für Apothekerinnen und Apotheker: Infektionskrankheiten. Österreichische Apothekerkammer. p. 103.